Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
13.68 USD | -1.87% | -1.34% | -35.44% |
Apr. 25 | Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained | MT |
Apr. 25 | Transcript : Sage Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.44% | 839M | |
+8.64% | 105B | |
-0.90% | 104B | |
+5.44% | 22.94B | |
-12.25% | 22.34B | |
-6.31% | 19.25B | |
-39.98% | 17.08B | |
-8.69% | 16.96B | |
+7.59% | 14.16B | |
+38.96% | 12.63B |
- Stock Market
- Equities
- SAGE Stock
- News Sage Therapeutics, Inc.
- Sage Therapeutics : Oppenheimer Adjusts Sage Therapeutics PT to $102 From $90, Maintains Outperform Rating